Aripiprazole as a dopamine partial agonist: positive and negative effects.
Glick
Ira D
ID
Duggal
Vandana
V
Hodulik
Charles
C
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000139:chemically induced / Q000209:etiology; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000627:therapeutic use*; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy*; D058830:Serotonin 5-HT2 Receptor Antagonists
D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D010879:Piperazines; D015363:Quinolones; D058830:Serotonin 5-HT2 Receptor Antagonists; D044282:Receptor, Serotonin, 5-HT1A; D000068180:Aripiprazole